» Articles » PMID: 30130104

Determinants of Oligonucleotide Selectivity of APOBEC3B

Overview
Date 2018 Aug 22
PMID 30130104
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

APOBEC3B (A3B) is a prominent source of mutation in many cancers. To date, it has been difficult to capture the native protein-DNA interactions that confer A3B's substrate specificity by crystallography due to the highly dynamic nature of wild-type A3B active site. We use computational tools to restore a recent crystal structure of a DNA-bound A3B C-terminal domain mutant construct to its wild type sequence, and run molecular dynamics simulations to study its substrate recognition mechanisms. Analysis of these simulations reveal dynamics of the native A3Bctd-oligonucleotide interactions, including the experimentally inaccessible loop 1-oligonucleotide interactions. A second series of simulations in which the target cytosine nucleotide was computationally mutated from a deoxyribose to a ribose show a change in sugar ring pucker, leading to a rearrangement of the binding site and revealing a potential intermediate in the binding pathway. Finally, apo simulations of A3B, starting from the DNA-bound open state, experience a rapid and consistent closure of the binding site, reaching conformations incompatible with substrate binding. This study reveals a more realistic and dynamic view of the wild type A3B binding site and provides novel insights for structure-guided design efforts for A3B.

Citing Articles

Regulatory interactions between APOBEC3B N- and C-terminal domains.

Braza M, Demir O, Ahn S, Morris C, Calvo-Tusell C, McGuire K bioRxiv. 2024; .

PMID: 39713448 PMC: 11661193. DOI: 10.1101/2024.12.11.628032.


Development of Allosteric Small Molecule APOBEC3B Inhibitors from Screening.

Jones K, Demir O, Wyllie M, Grillo M, Morris C, Hirakis S bioRxiv. 2024; .

PMID: 38712210 PMC: 11071470. DOI: 10.1101/2024.04.25.591187.


Exploring ABOBEC3A and APOBEC3B substrate specificity and their role in HPV positive head and neck cancer.

Papini C, Wang Z, Kudalkar S, Schrank T, Tang S, Sasaki T iScience. 2022; 25(10):105077.

PMID: 36164654 PMC: 9508485. DOI: 10.1016/j.isci.2022.105077.


APOBECs and Herpesviruses.

Cheng A, Moraes S, Shaban N, Fanunza E, Bierle C, Southern P Viruses. 2021; 13(3).

PMID: 33671095 PMC: 7998176. DOI: 10.3390/v13030390.


Active site plasticity and possible modes of chemical inhibition of the human DNA deaminase APOBEC3B.

Shi K, Demir O, Carpenter M, Banerjee S, Harki D, Amaro R FASEB Bioadv. 2020; 2(1):49-58.

PMID: 32123856 PMC: 6996314. DOI: 10.1096/fba.2019-00068.


References
1.
Vangaveti S, Ranganathan S, Chen A . Advances in RNA molecular dynamics: a simulator's guide to RNA force fields. Wiley Interdiscip Rev RNA. 2016; 8(2). DOI: 10.1002/wrna.1396. View

2.
Venkatesan S, Rosenthal R, Kanu N, McGranahan N, Bartek J, Quezada S . Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Ann Oncol. 2018; 29(3):563-572. PMC: 5888943. DOI: 10.1093/annonc/mdy003. View

3.
Martin A, Salamango D, Serebrenik A, Shaban N, Brown W, Donati F . A fluorescent reporter for quantification and enrichment of DNA editing by APOBEC-Cas9 or cleavage by Cas9 in living cells. Nucleic Acids Res. 2018; 46(14):e84. PMC: 6101615. DOI: 10.1093/nar/gky332. View

4.
Case D, Cheatham 3rd T, Darden T, Gohlke H, Luo R, Merz Jr K . The Amber biomolecular simulation programs. J Comput Chem. 2005; 26(16):1668-88. PMC: 1989667. DOI: 10.1002/jcc.20290. View

5.
Wagener R, Alexandrov L, Montesinos-Rongen M, Schlesner M, Haake A, Drexler H . Analysis of mutational signatures in exomes from B-cell lymphoma cell lines suggest APOBEC3 family members to be involved in the pathogenesis of primary effusion lymphoma. Leukemia. 2015; 29(7):1612-5. DOI: 10.1038/leu.2015.22. View